Circadian rhythms of cellular immunity in rheumatoid arthritis: A hypothesis-generating study

Clinical and Experimental Rheumatology

Volumn 33, Issue 1, 2015, Pages 34-43

  Spies, Cornelia M ^a   Hoff, Paula ^a,b   Mazuch, Jeannine ^a   Gaber, Timo ^a,b   Maier, Bert ^a   Strehl, Cindy ^a,b   Hahne, Martin ^a,b   Jakstadt, Manuela ^a,b   Huscher, Dörte ^a,b   Burmester, Gerd Rüdiger ^a   Detert, Jacqueline ^a   Kramer, Achim ^a   Buttgereit, Frank ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b DEUTSCHES RHEUMA FORSCHUNGSZENTRUM   (Germany)

Author keywords

Circadian clock; Circadian rhythm; Clock genes; Monocytes; Postmenopausal; Rheumatoid arthritis

Indexed keywords

C REACTIVE PROTEIN; CD14 ANTIGEN; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; MONOCYTE CHEMOTACTIC PROTEIN 1; PER2 PROTEIN; AUTACOID; BIOLOGICAL MARKER; CIRCADIAN RHYTHM SIGNALING PROTEIN; CYTOKINE; MESSENGER RNA; PER2 PROTEIN, HUMAN; PER3 PROTEIN, HUMAN;

ADULT; ARTICLE; BMAL1 LUCIFERASE BIOLUMINESCENCE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL FUNCTION; CELL POPULATION; CELLULAR IMMUNITY; CIRCADIAN RHYTHM; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE MULTIPLEX SUSPENSION ARRAY; FEMALE; FLOW CYTOMETRY; GENE; GENE EXPRESSION; HUMAN; HUMAN CELL; INVESTIGATIVE PROCEDURES; MACROPHAGE; MIDDLE AGED; MOLECULAR DYNAMICS; MONOCYTE; PER2 GENE; PER3 GENE; POSTMENOPAUSE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RHEUMATOID ARTHRITIS; ADAPTATION; AGED; BLOOD; CASE CONTROL STUDY; GENETICS; HUMORAL IMMUNITY; IMMUNOLOGY; METABOLISM; PATHOPHYSIOLOGY; PILOT STUDY; TIME;

ADAPTATION, PHYSIOLOGICAL; AGED; ANTIGENS, CD14; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CIRCADIAN RHYTHM; CYTOKINES; FEMALE; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; INFLAMMATION MEDIATORS; MACROPHAGES; MIDDLE AGED; MONOCYTES; PERIOD CIRCADIAN PROTEINS; PILOT PROJECTS; POSTMENOPAUSE; RNA, MESSENGER; TIME FACTORS;

EID: 84928696499     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. CUTOLO M, STRAUB RH, BUTTGEREIT F: Circadian rhythms of nocturnal hormones in rheumatoid arthritis: translation from bench to bedside. Ann Rheum Dis 2008; 67: 905-8.
2. STRAUB RH, CUTOLO M: Circadian rhythms in rheumatoid arthritis: implications for pathophysiology and therapeutic management. Arthritis Rheum 2007; 56: 399-408.
3. BELLAMY N, SOTHERN RB, CAMPBELL J, BUCHANAN WW: Circadian rhythm in pain, stiffness, and manual dexterity in rheumatoid arthritis: relation between discomfort and disability. Ann Rheum Dis 1991; 50: 243-8.
4. HARKNESS JA, RICHTER MB, PANAYI GS et al.: Circadian variation in disease activity in rheumatoid arthritis. Br Med J (Clin Res Ed) 1982; 284: 551-4.
5. KOWANKO IC, KNAPP MS, POWNALL R, SWANNELL AJ: Domiciliary self-measurement in the rheumatoid arthritis and the demonstration of circadian rhythmicity. Ann Rheum Dis 1982; 41: 453-5.
6. WESTHOFF G, BUTTGEREIT F, GROMNICA-IHLE E, ZINK A: Morning stiffness and its influence on early retirement in patients with recent onset rheumatoid arthritis. Rheumatology (Oxford) 2008; 47: 980-4.
7. PETROVSKY N, McNAIR P, HARRISON LC: Diurnal rhythms of pro-inflammatory cyto-kines: regulation by plasma cortisol and therapeutic implications. Cytokine 1998; 10: 307-12.
8. ARVIDSON NG, GUDBJORNSSON B, ELFMAN L, RYDEN AC, TOTTERMAN TH, HALLGREN R: Circadian rhythm of serum interleukin-6 in rheumatoid arthritis. Ann Rheum Dis 1994; 53: 521-4.
9. PERRY MG, KIRWAN JR, JESSOP DS, HUNT LP: Overnight variations in cortisol, interleukin 6, tumour necrosis factor alpha and other cytokines in people with rheumatoid arthritis. Ann Rheum Dis 2009; 68: 63-8.
10. BUTTGEREIT F, DOERING G, SCHAEFFLER A et al.: Efficacy of modified-release versus standard prednisone to reduce duration of morning stiffness of the joints in rheumatoid arthritis (CAPRA-1): a double-blind, randomised controlled trial. Lancet 2008; 371: 205-14.
11. BUTTGEREIT F, DOERING G, SCHAEFFLER A et al.: Targeting pathophysiological rhythms: prednisone chronotherapy shows sustained efficacy in rheumatoid arthritis. Ann Rheum Dis 2010; 69: 1275-80.
12. BUTTGEREIT F, MEHTA D, KIRWAN J et al.: Low-dose prednisone chronotherapy for rheumatoid arthritis: a randomised clinical trial (CAPRA-2). Ann Rheum Dis 2013; 72: 204-10.
13. ESQUIFINO AI, SELGAS L, ARCE A, MAGGIORE VD, CARDINALI DP: Twenty-four-hour rhythms in immune responses in rat submaxillary lymph nodes and spleen: effect of cyclosporine. Brain Behav Immun 1996; 10: 92-102.
14. ARJONA A, SARKAR DK: Circadian oscillations of clock genes, cytolytic factors, and cytokines in rat NK cells. J Immunol 2005; 174: 7618-24.
15. KAWATE T, ABO T, HINUMA S, KUMAGAI K: Studies of the bioperiodicity of the immune response. II. Co-variations of murine T and B cells and a role of corticosteroid. J Immunol 1981; 126: 1364-7.
16. DIMITROV S, BENEDICT C, HEUTLING D, WESTERMANN J, BORN J, LANGE T: Cortisol and epinephrine control opposing circadian rhythms in T cell subsets. Blood 2009; 113: 5134-43.
17. MAZZOCCOLI G, DE CATA A, GRECO A et al.: Aging related changes of circadian rhythmicity of cytotoxic lymphocyte subpopulations. J Circadian Rhythms 2010; 8: 6.
18. YOUNG MR, MATTHEWS JP, KANABROCKI EL, SOTHERN RB, ROITMAN-JOHNSON B, SCHEVING LE: Circadian rhythmometry of serum interleukin-2, interleukin-10, tumor necrosis factor-alpha, and granulocyte-macrophage colony-stimulating factor in men. Chronobiol Int 1995; 12: 19-27.
19. KELLER M, MAZUCH J, ABRAHAM U et al.: A circadian clock in macrophages controls inflammatory immune responses. Proc Natl Acad Sci USA 2009; 106: 21407-12.
20. ROENNEBERG T, WIRZ-JUSTICE A, MERROW M: Life between clocks: daily temporal patterns of human chronotypes. J Biol Rhythms 2003; 18: 80-90.
21. ARNETT FC, EDWORTHY SM, BLOCH DA et al.: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-24.
22. PREVOO ML, Van 't HOF MA, KUPER HH, van LEEUWEN MA, van de PUTTE LB, van RIEL PL: Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995; 38: 44-8.
23. FRIES JF, SPITZ P, KRAINES RG, HOLMAN HR: Measurement of patient outcome in arthritis. Arthritis Rheum 1980; 23: 137-45.
24. WARE JE, KOSINSKI M, KELLER SD: SF-36 Physical and mental health summary scales: a user's manual. Boston: The Health Institute, New England Medical Center, 1994.
25. SMETS EM, GARSSEN B, BONKE B, DE HAES JC: The Multidimensional Fatigue Inventory (MFI) psychometric qualities of an instrument to assess fatigue. J Psychosom Res 1995; 39: 315-25.
26. SMETS EM, GARSSEN B, CULL A, de HAES JC: Application of the multidimensional fatigue inventory (MFI-20) in cancer patients receiving radiotherapy. Br J Cancer 1996; 73: 241-5.
27. FREYNHAGEN R, BARON R, GOCKEL U, TOLLE TR: painDETECT: a new screening questionnaire to identify neuropathic components in patients with back pain. Curr Med Res Opin 2006; 22: 1911-20.
28. BROWN SA, FLEURY-OLELA F, NAGOSHI E et al.: The period length of fibroblast circadian gene expression varies widely among human individuals. PLoS Biol 2005; 3: e338.
29. GIBBS JE, RAY DW: The role of the circadian clock in rheumatoid arthritis. Arthritis Res Ther 2013; 15: 205.
30. STRAUB RH, CUTOLO M, BUTTGEREIT F, PONGRATZ G: Energy regulation and neuroendocrine-immune control in chronic inflammatory diseases. J Intern Med 2010; 267: 543-60.
31. CERMAKIAN N, LANGE T, GOLOMBEK D et al.: Crosstalk between the circadian clock circuitry and the immune system. Chronobiol Int 2013; 30: 870-88.
32. LANGE T, DIMITROV S, BORN J: Effects of sleep and circadian rhythm on the human immune system. Ann N Y Acad Sci 2010; 1193: 48-59.
33. DEKKERS JC, GEENEN R, GODAERT GL, van DOORNEN LJ, BIJLSMA JW: Diurnal rhythm of salivary cortisol levels in patients with recent-onset rheumatoid arthritis. Arthritis Rheum 2000; 43: 465-7.
34. NEECK G, FEDERLIN K, GRAEF V, RUSCH D, SCHMIDT KL: Adrenal secretion of cortisol in patients with rheumatoid arthritis. J Rheumatol 1990; 17: 24-9.
35. CROFFORD LJ, KALOGERAS KT, MASTORAKOS G et al.: Circadian relationships between interleukin (IL)-6 and hypothalamic-pituitary-adrenal axis hormones: failure of IL-6 to cause sustained hypercortisolism in patients with early untreated rheumatoid arthritis. J Clin Endocrinol Metab 1997; 82: 1279-83.
36. HAAS S, STRAUB RH: Disruption of rhythms of molecular clocks in primary synovial fibroblasts of patients with osteoarthritis and rheumatoid arthritis, role of IL-1beta/TNF. Arthritis Res Ther 2012; 14: R122.
37. KOURI VP, OLKKONEN J, KAIVOSOJA E et al.: Circadian timekeeping is disturbed in rheumatoid arthritis at molecular level. PloS one 2013; 8: e54049.
38. YOSHIDA K, HASHIRAMOTO A, OKANO T, YAMANE T, SHIBANUMA N, SHIOZAWA S: TNF-alpha modulates expression of the circadian clock gene Per2 in rheumatoid synovial cells. Scand J Rheumatol 2013; 42: 276-80.
39. HASHIRAMOTO A, YAMANE T, TSUMIYAMA K et al.: Mammalian clock gene Cryptochrome regulates arthritis via proinflammatory cytokine TNF-alpha. J Immunol 2010; 184: 1560-5.
40. HAYASHI M, SHIMBA S, TEZUKA M: Characterization of the molecular clock in mouse peritoneal macrophages. Biol Pharm Bull 2007; 30: 621-6.
41. TO H, IRIE S, TOMONARI M, WATANABE Y, KITAHARA T, SASAKI H: Therapeutic index of methotrexate depends on circadian cycling of tumour necrosis factor-alpha in collagen-induced arthritic rats and mice. J Pharm Pharmacol 2009; 61: 1333-8.
42. TO H, YOSHIMATSU H, TOMONARI M et al.: Methotrexate chronotherapy is effective against rheumatoid arthritis. Chronobiol Int 2011; 28: 267-74.
43. JONES SA: Directing transition from innate to acquired immunity: defining a role for IL-6. J Immunol 2005; 175: 3463-8.
44. HWANG SY, KIM JY, KIM KW et al.: IL-17 induces production of IL-6 and IL-8 in rheumatoid arthritis synovial fibroblasts via NF-kappaB-and PI3-kinase/Akt-dependent pathways. Arthritis Res Ther 2004; 6: R120-8.
45. BOLLINGER T, BOLLINGER A, SKRUM L, DIMITROV S, LANGE T, SOLBACH W: Sleep-dependent activity of T cells and regulatory T cells. Clin Exp Immunol 2009; 155: 231-8.
46. NIEHAUS GD, ERVIN E, PATEL A, KHANNA K, VANEK VW, FAGAN DL: Circadian variation in cell-adhesion molecule expression by normal human leukocytes. Can J Physiol Pharmacol 2002; 80: 935-40.
47. MOOTS RJ, NAISBETT-GROET B: The efficacy of biologic agents in patients with rheumatoid arthritis and an inadequate response to tumour necrosis factor inhibitors: a systematic review. Rheumatology (Oxford) 2012; 51: 2252-61.
48. BURMESTER GR, MARIETTE X, MONTECUCCO C et al.: Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the Research in Active Rheumatoid Arthritis (ReAct) trial. Ann Rheum Dis 2007; 66: 732-9.
49. BOMBARDIERI S, RUIZ AA, FARDELLONE P et al.: Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF-antagonist therapy in clinical practice. Rheumatology (Oxford) 2007; 46: 1191-9.
50. BAKKER MF, JACOBS JW, WELSING PM et al.: Early clinical response to treatment predicts 5-year outcome in RA patients: follow-up results from the CAMERA study. Ann Rheum Dis 2011; 70: 1099-103.